Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease.
10.1007/s11655-022-3307-3
- Author:
Baran GHEZELBASH
1
;
Nader SHAHROKHI
2
;
Mohammad KHAKSARI
3
;
Gholamreza ASADIKARAM
4
;
Maryam SHAHROKHI
5
;
Sara SHIRAZPOUR
6
Author Information
1. Physiology Research Center, Kerman University of Medical Sciences, Kerman, 7616914115, Iran.
2. Physiology Research Center, Kerman University of Medical Sciences, Kerman, 7616914115, Iran. nshahrokhisa@yahoo.com.
3. Endocrinology, and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, 7616914115, Iran.
4. Department of Biochemistry, School of Medicine, Kerman University of Medical Sciences, Kerman, 7616914115, Iran.
5. Department of Medical Science, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, 713414336, Iran.
6. Department of Physiology and Pharmacology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, 7616914115, Iran.
- Publication Type:Journal Article
- Keywords:
Ayurvedic medicine;
Shilajit;
adipokines;
cytokines;
dietary supplement;
glucose;
insulin;
non-alcoholic fatty liver disease
- MeSH:
Adiponectin;
Animals;
Cytokines;
Diet, High-Fat;
Glucose;
Insulin Resistance;
Interleukin-10;
Liver;
Male;
Minerals;
Non-alcoholic Fatty Liver Disease/pathology*;
Pioglitazone/therapeutic use*;
Rats;
Rats, Wistar;
Resins, Plant;
Resistin/therapeutic use*;
Tumor Necrosis Factor-alpha
- From:
Chinese journal of integrative medicine
2022;28(6):531-537
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To evaluate the effect of Shilajit, a medicine of Ayurveda, on the serum changes in cytokines and adipokines caused by non-alcoholic fatty liver disease (NAFLD).
METHODS:After establishing fatty liver models by feeding a high-fat diet (HFD) for 12 weeks, 35 Wistar male rats were randomly divided into 5 groups, including control (standard diet), Veh (HFD + vehicle), high-dose Shilajit [H-Sh, HFD + 250 mg/(kg·d) Shilajit], low-dose Shilajit [L-Sh, HFD + 150 mg/(kg·d) Shilajit], and pioglitazone [HFD + 10 mg/(kg·d) pioglitazone] groups, 7 rats in each group. After 2-week of gavage administration, serum levels of glucose, insulin, interleukin 1beta (IL-1β), IL-6, IL-10, tumor necrosis factor-alpha (TNF-α), adiponectin, and resistin were measured, and insulin resistance index (HOMA-IR) was calculated.
RESULTS:After NAFLD induction, the serum level of IL-10 significantly increased and serum IL-1β, TNF-α levels significantly decreased by injection of both doses of Shilajit and pioglitazone (P<0.05). Increases in serum glucose level and homeostasis model of HOMA-IR were reduced by L-Sh and H-Sh treatment in NAFLD rats (P<0.05). Both doses of Shilajit increased adiponectin and decreased serum resistin levels (P<0.05).
CONCLUSION:The probable protective role of Shilajit in NAFLD model rats may be via modulating the serum levels of IL-1β, TNF-α, IL-10, adipokine and resistin, and reducing of HOMA-IR.
